Commercial manager for hematology and NF1 franchise. Responsible of developing CLL and MCL indications for Calquence (Acalabrutinib) as well as NF1 for Koselugo (Selumetinib) in Mexico* Launch of MCL in public market, with specific sales to IMSS, ISSSTE, SEDENA and decentralized institutions. Obtained first national tender for the brand (AAMATES) and first contract in ISSSTE. * Deployment of strategy for boosting CLL & MCL in private market, reaching 37% M.S. and an E.I. of 135 (FY2022 in approved indications)* Launch of Koselugo (Selumetinib) for Neurofibromatosis type I to private market and submission to NHC* Hematology: In charge of marketing and sales teams * NF1 - Virtual promotion

Regional sales manager for solid tumors portfolio. Central and Northwest Mexico States.

Responsible in Mexico, Costa Rica, Panamá and rest of Central America for cITP market, development of new indications (pITP, sAA, others) and also coordinating cross functional teams to get access to the public health system. • Management of Revolade and execution of private market strategy to penetrate segment (80% of sales) and OG institutions. Sales growth full year vs 2015; 36%• Design, coordination and follow up of government access plan –in coordination with access department to get reimbursement at ISSSTE, IMSS and other government institutions• Follow up to Exjade strategy implemented back in 2015. Good brand growth, +18% vs 2015 (Regional: +11%, WW 9%). Profitability above budget. • In charge of 1 colleague

Responsible for Exjade (Iron overload in hematologic patients) and Jakavi (Myelofibrosis -Orphan drug)• Exjade’s strategy rethinking - brand repositioning and identification of new business and markets. 13% sales increase vs. 2014 full year as well as a demand increase of 20% in IMSS (60% of total sales). Healthy inventories, wholesaler management and forecast accuracy of 90% to become brand profitable again• Management of an orphan drug (Jakavi) in myelofibrosis and policitemia vera reaching sales of 20 million MXN in private market and other government institutions. 65% growth vs. 2014 YE. Sales to insurance companies and patient support program management• In charge of 2 colleagues

Management of renal anaemia portfolio; Recormon and Mircera (launch of the product in 2009) Also in charge of transplantation products: CellCept, Valcyte and Zenapax. All products face generics competition and main achievements are related to meet revenues that leads the organization to maximize cash flow and gain of market share with recently launched product.

In charge of Severe acne (Roaccutane) and Psoriasis (Neotigason) products as well as launch of Atopic dermatitis topical immunomodulator (Protopic). Main achievements:To gain 17% market share in a generics market with Roaccutan (baseline 45%, endpoint 62% M.S.) and to reach 30% M.S. with Protopic -this is 3 times the M.S. of main generic which was launched 6 months before our product.

In charge of mature products in NSAIDs market; Febrax and Naxen. Main achievement: Febrax reduced its fall in sales: from 20 to 4% in units and from 12 to 0% in values

Associate in charge of market analysis, market research for antiinflamatories and analgesics (Febrax, Dolac, Naxen, etc) as well as responsibilities of junior product manager with Febrax

Sales representative for antiinflamatories and antibiotics with diverse territories within Mexico City and Toluca